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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of health claims related to 
non-characterised micro-organisms (ID 2936, 2937, 2938, 2941, 2944, 2965, 
2968, 2969, 3035, 3047, 3056, 3059, further assessment) pursuant to Article 
13(1) of Regulation (EC) No 1924/2006
1 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies 
(NDA) was asked to provide a scientific opinion on health claims pursuant to Article 13 of Regulation (EC) No 
1924/2006 in the framework of further assessment. This opinion addresses the scientific substantiation of health 
claims related to microorganisms for which the Panel considered in previous opinions that the data provided were 
not  sufficient  to  characterise  the  microorganisms  in  question.  The  criteria  used  by  the  Panel  for  the 
characterisation of food constituents that are bacteria and combinations thereof, which are the subject of health 
claims,  are:  species  identification  by  DNA-DNA  hybridisation  or  16S  rRNA  gene  sequence analysis and/or 
sequence analysis of other relevant genetic markers; strain identification by DNA macrorestriction followed by 
pulsed-field  gel  electrophoresis,  randomly  amplified  polymorphic  DNA  analysis,  or  other  internationally 
accepted genetic typing molecular methods. Only when these two criteria are fulfilled is the bacterium considered 
to be sufficiently characterised. In the case of combinations of several bacteria, the Panel considers that if one 
microorganism  used  in  the  combination  is  not  sufficiently  characterised,  the  combination  proposed  is  not 
sufficiently characterised. The Panel considers that the food constituents which are the subject of this opinion are 
not sufficiently characterised. On the basis of the data presented, the Panel concludes that a cause and effect 
relationship cannot be established between the consumption of the food constituents which are the subject of this 
opinion and the claimed effects. © European Food Safety Authority, 2012 
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SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies (NDA) was asked to provide a scientific opinion on a list of health claims pursuant to 
Article 13 of Regulation (EC) No 1924/2006. The Commission has agreed with EU Member States 
that a certain number of Article 13 health claims would be eligible for further assessment by EFSA in 
order to be able to take a final decision on whether or not to include these claims in the list of 
permitted health claims. This opinion addresses the scientific substantiation of health claims related to 
microorganisms for which the Panel considers that the data provided are not sufficient to characterise 
the microorganisms in question. The scientific substantiation is based on the information provided by 
the competent Authority of Italy for further assessment of this claim. 
The  criteria  used  by  the  Panel  for  the characterisation of food constituents that are bacteria and 
combinations thereof, which are the subject of health claims, are: 
  Species identification by DNA-DNA hybridisation or 16S rRNA gene sequence analysis and/or 
sequence analysis of other relevant genetic markers. 
  Strain  identification  by  DNA  macrorestriction  followed  by  pulsed-field  gel  electrophoresis 
(PFGE),  randomly  amplified  polymorphic  DNA  analysis  (RAPD),  or  other  internationally 
accepted genetic typing molecular methods. 
Only when these two criteria are fulfilled is the bacterium considered to be sufficiently characterised. 
In the case of combinations of several bacteria, the Panel considers that if one microorganism used in 
the  combination  is  not  sufficiently  characterised,  the  combination  proposed  is  not  sufficiently 
characterised. 
The foods/food constituents that are the subject of this opinion are: 
-  Bifidobacterium breve BR03 related to the following claimed effect: “intestinal mobility” (ID 
2936). 
-  Bifidobacterium longum BL03 related to the following claimed effect: “intestinal mobility” 
(ID 2937). 
-  A combination of Bifidobacterium breve BR03 and Lactobacillus plantarum LP01 related to 
the following claimed effect: “reducing gastrointestinal discomfort associated with increased 
transit time” (ID 2938). 
-  A  combination  of  Bifidobacterium  animalis  subsp.  lactis  BS01,  Lactobacillus  rhamnosus 
LR04, Lactobacillus plantarum LP02 and short-chain fructo-oligosaccharides related to the 
following claimed effect: “defence against upper respiratory tract infections” (ID 2941). 
-  A combination of Lactobacillus acidophilus LA02 and Lactobacillus plantarum LP01 related 
to the following claimed effect: “relief of abdominal discomfort and pain” (ID 2944). 
-  Lactobacillus plantarum LP01 related to the following claimed effect: “intestinal mobility” 
(ID 2965). 
-  Lactobacillus rhamnosus LR04 related to the following claimed effect: “balancing intestinal 
flora, improves skin, scalp and hair health” (ID 2968) and “reduce the daily number of bowel 
movements” (ID 2969). 
-  Bifidobacterium  adolescentis  BA02  related  to  the  following  claimed  effect:  “intestinal 
motility” (ID 3035). Health claims related to non-characterised microorganisms (further assessment) 
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-  A  combination  of  Bifidobacterium  animalis  subsp.  lactis  BS01,  Lactobacillus  rhamnosus 
LR04,  Lactobacillus  rhamnosus  LR05,  Lactobacillus  plantarum  LP01,  Lactobacillus 
plantarum LP02 and short-chain fructo-oligosaccharides or galacto-oligosaccharides related to 
the following claimed effect: “defence against upper respiratory tract infections” (ID 3047). 
-  Bifidobacterium longum W11 related to the following claimed effect: “relief of abdominal 
discomfort and bloating” (ID 3056). 
-  A  combination  of  Bifidobacterium  animalis  subsp.  lactis  BS01,  Lactobacillus  rhamnosus 
LR04,  Lactobacillus  plantarum  LP02,  lactoferrin  and  short-chain  fructo-oligosaccharides 
related to the following claimed effect: “defence against upper respiratory tract infections”. 
The  Panel  considers  that  the  food  constituents  which  are  the  subject  of  this  opinion  are  not 
sufficiently characterised. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship cannot be 
established between the consumption of the food constituents which are the subject of this opinion 
and the proposed claimed effects. 
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INTRODUCTION 
The Commission has agreed with EU Member States that a certain number of Article 13 health claims 
would be eligible for further assessment by EFSA in order to be able to take a final decision on 
whether or not to include these claims in the list of permitted health claims. These claims include 
already assessed claims related to micro-organisms which the Panel considered to be not sufficiently 
characterised and claims for which the NDA Panel concluded that there was insufficient evidence to 
establish a cause and effect relationship between the consumption of the food and the claimed effect. 
Following an opinion of the NDA Panel on a health claim pursuant to Article 13 of Regulation (EC) 
No 1924/2006
4 in which the Panel concluded that the data available were not sufficient to characterise 
Bifidobacterium breve BR 03 (DSM 16604) (ID 2936), Bifidobacterium breve BL 03 (DSM 16603) 
(ID 2937), a combination of Bifidobacterium breve BR 03 (DSM 16604) and Lactobacillus plantarum 
LP 01 (LMG P-21021) (ID 2938), a combination of Bifidobacterium lactis BS 01 (LMG P-21384), 
Lactobacillus rhamnosus LR 04 (DSM 16605) and Lactobacillus plantarum LP 02 (LMG P-21020) 
(ID 2941), a combination of Lactobacillus acidophilus LA 02 (LMG P-21381) and Lactobacillus 
plantarum  LP  01  (LMG  P-21021)  (ID  2944),  Lactobacillus  plantarum  LP  01  (LMG  P-21021) 
(ID 2965),  Lactobacillus  rhamnosus  (ID  2968),  Lactobacillus  rhamnosus  LR  04  (DSM  16605) 
(ID 2969),  Bifidobacterium  adolescentis  BA  02  (DSM  17103)  (ID  3035),  a  combination  of 
Lactobacillus plantarum LP 01 (LMG P-21021), Lactobacillus plantarum LP 02 (LMG P-21020), 
Lactobacillus rhamnosus LR 04 (DSM 16605), Lactobacillus rhamnosus LR 05 (DSM 19739) and 
Bifidobacterium  lactis  BS  01  (LMG  P-21384)  (ID  3047),  Bifidobacterium  longum  W11  (LMG 
P-21586)  (ID  3056),  and  a  combination  of  Bifidobacterium  lactis  BS  01  (LMG  P-21384), 
Lactobacillus rhamnosus LR 04 (DSM 16605) and Lactobacillus plantarum LP 02 (LMG P-21020) 
(ID 3059) (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2010), EFSA received 
additional information from the competent Authority of Italy for further assessment of this claim. The 
information provided in the framework of further assessment for the health claims which are the 
subject of this opinion is tabulated in Appendix C. 
ASSESSMENT 
The  approach  used  in  the  evaluation  of  Article  13(1)  health  claims  is  explained  in  the  general 
guidance for stakeholders on the evaluation of Article 13.1, 13.5 and 14 health claims
5.  
In assessing each specific food/health relationship that forms the basis of a health claim the NDA 
Panel considers the extent to which:  
1. the food/constituent is defined and characterised;  
2. the claimed effect is defined and is a beneficial physiological effect (“beneficial to human health”);  
3. a cause and effect relationship is established between the consumption of the food/constituent and 
the claimed effect (for the target group under the proposed conditions of use).  
Substantiation of the claim is dependent on a favourable outcome of the assessment of 1, 2 and 3 
above. Thus, a cause and effect relationship is considered not to be established if the outcome of any 
one of these assessments is unfavourable.  
                                                       
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
5  EFSA Panel on Di etetic Products, Nutrition and Allergies (NDA), 2011. General guidance for stakeholders on the 
evaluation of Article 13.1, 13.5 and 14 health claims. EFSA Journal, 9(4):2135, 24 pp. Health claims related to non-characterised microorganisms (further assessment) 
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For a claim, each relationship between a food/constituent and a claimed effect is assessed separately, 
and individual assessments are combined, as appropriate, to form coherent opinions. 
1.  Characterisation of the food/constituent 
The  criteria  used  by  the  Panel  for  the characterisation of food constituents that are bacteria and 
combinations  thereof,  which  are  the  subject  of  health  claims,  are  specified  in  previous  opinions 
(EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2009, 2010, 2011) and are: 
  Species identification by DNA-DNA hybridisation or 16S rRNA gene sequence analysis and/or 
sequence analysis of other relevant genetic markers. 
  Strain  identification  by  DNA  macrorestriction  followed  by  pulsed-field  gel  electrophoresis 
(PFGE),  randomly  amplified  polymorphic  DNA  analysis  (RAPD),  or  other  internationally 
accepted genetic typing molecular methods. 
Only when these two criteria are fulfilled is the bacterium considered to be sufficiently characterised. 
In the case of combinations of several bacteria, the Panel considers that if one microorganism used in 
the  combination  is  not  sufficiently  characterised,  the  combination  proposed  is  not  sufficiently 
characterised. 
1.1.  Bifidobacterium breve BR03 (ID 2936) 
The food constituent that is the subject of the health claim is Bifidobacterium breve BR03 related to 
the following claimed effect: “intestinal mobility”. 
For B. breve BR03, a culture collection number from the German Collection of Microorganisms and 
Cell  Cultures  (DSMZ),  DSM  16604,  was  provided.  The  DSMZ  is  an  internationally  recognised 
culture collection which has the status of an International Depositary Authority under the Budapest 
Treaty. In the DSMZ, cultures can be deposited in a restricted-access collection as patent deposits. 
Data on the identification and characterisation of B. breve BR03 at species and strain level, by using 
both  phenotypic  (enzymatic  activity  pattern,  carbohydrate  fermentation  profile,  PAGE,  antibiotic 
resistance profiles) and genotypic (species-specific PCR, ERIC-PCR, PFGE) methods, were provided 
in the application for further assessment and in the accompanying references (Del Piano et al., 2010). 
The Panel notes that the use of species-specific PCR as unique molecular technique is insufficient to 
ensure the correct assignation of the species identity.  
The Panel considers that the food constituent, B. breve BR03, which is the subject of the claim, is not 
sufficiently characterised.  
The  Panel  concludes  that  a  cause  and  effect  relationship  cannot  be  established  between  the 
consumption of B. breve BR03 and the claimed effect considered in this section. 
1.2.  Bifidobacterium longum BL03 (ID 2937) 
The food constituent that is the subject of the health claim is Bifidobacterium longum BL03 related to 
the following claimed effect: “intestinal mobility”.  
For B. longum BL03, a culture collection number from the DSMZ, DSM 16603, was provided. Data 
on the identification and characterisation of B. longum BL03 at species and strain level, by using both 
phenotypic (enzymatic activity pattern, carbohydrate fermentation profile, PAGE, antibiotic resistance 
profiles) and genotypic (species-specific PCR, PFGE) methods, were provided in the application for Health claims related to non-characterised microorganisms (further assessment) 
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further  assessment.  The  Panel  notes  that  the  use  of  species-specific  PCR  as  unique  molecular 
technique is insufficient to ensure the correct assignation of the species identity. 
The Panel considers that the food constituent, B. longum BL03, which is the subject of the claim, is 
not sufficiently characterised. 
The  Panel  concludes  that  a  cause  and  effect  relationship  cannot  be  established  between  the 
consumption of B. longum BL03 and the claimed effect considered in this section. 
1.3.  A  combination  of  Bifidobacterium  breve  BR03  and  Lactobacillus  plantarum  LP01 
(ID 2938) 
The food constituent that is the subject of the health claim is a combination of Bifidobacterium breve 
BR03 and Lactobacillus plantarum LP01 related to the following claimed effect: “reducing gastro-
intestinal discomfort associated with increased transit time”. 
For B. breve BR03, a culture collection number from the DSMZ, DSM 16604, was provided. Data on 
the identification and characterisation of B. breve BR03 at species and strain level, by using both 
phenotypic (enzymatic activity pattern, carbohydrate fermentation profile, PAGE, antibiotic resistance 
profiles) and genotypic (ERIC-PCR, species-specific PCR, PFGE) methods, were provided in the 
application for further assessment and in the accompanying references (Del Piano et al., 2010). The 
Panel notes that the use of species-specific PCR as unique molecular technique is insufficient to 
ensure the correct assignation of the species identity, and considers that the strain B. breve BR03 is 
not sufficiently characterised. 
For L. plantarum LP01, a culture collection number from the Belgian Co-ordinated Collections of 
Microorganisms (BCCM/LMG), LMG P-21021, was provided. The BCCM/LMG is an internationally 
recognised culture collection which has the status of an International Depositary Authority under the 
Budapest Treaty. In the LMG, cultures can be deposited in a restricted-access collection for safe 
deposit or for patent purposes. Data on the identification and characterisation of L. plantarum LP01 at 
species  and  strain  level,  by  using  both  phenotypic  (enzymatic  activity  pattern,  carbohydrate 
fermentation  profile,  PAGE,  antibiotic  resistance  profiles)  and  genotypic  (species-specific  PCR, 
PFGE) methods, were provided in the application for further assessment and in the accompanying 
references (Del Piano et al., 2010). The Panel notes that the use of species-specific PCR as unique 
molecular  technique  is  insufficient  to  ensure  the  correct  assignation  of  the  species  identity,  and 
considers that the strain L. plantarum LP01 is not sufficiently characterised. 
The Panel considers that the food constituent, a combination of B. breve BR03 and L. plantarum 
LP01, which is the subject of the health claim, is not sufficiently characterised. 
The  Panel  concludes  that  a  cause  and  effect  relationship  cannot  be  established  between  the 
consumption of a  combination of  B. breve BR03 and L. plantarum LP01 and the claimed effect 
considered in this section. 
1.4.  A combination of Bifidobacterium animalis subsp. lactis BS01, Lactobacillus rhamnosus 
LR04, Lactobacillus plantarum LP02 and short-chain fructo-oligosaccharides (ID 2941) 
The food constituent that is the subject of the health claim is a combination of Bifidobacterium lactis 
BS01,  Lactobacillus  rhamnosus  LR04,  Lactobacillus  plantarum  LP02  and  short-chain  fructo-
oligosaccharides  related  to  the  following  claimed  effect:  “defence  against  upper  respiratory  tract 
infections”.  Health claims related to non-characterised microorganisms (further assessment) 
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For B. lactis BS01, hereafter B. animalis subsp. lactis BS01, since the species B. lactis has been 
reclassified as B. animalis subsp. lactis (Masco et al., 2004), a culture collection number from the 
BCCM/LMG,  LMG  P-21384,  was  provided.  Data  on  the  identification  and  characterisation  of 
B. lactis  BS01  at  species  and  strain  level,  by  using  both  phenotypic  (enzymatic  activity  pattern, 
carbohydrate  fermentation  profile,  PAGE,  antibiotic  resistance  profiles)  and  genotypic  (species-
specific PCR, Rep-PCR, MLST, and genome sequencing [publicly available at genbank, Project ID 
59607]) methods, were provided in the application for further assessment and in the accompanying 
references (Del Piano et al., 2010). The Panel considers that the strain B. animalis subsp. lactis BS01 
is sufficiently characterised. 
For L. rhamnosus LR04 a culture collection number from the DSMZ, DSM 16605, was provided. 
Data on the identification and characterisation of L. rhamnosus LR04 at species and strain level, by 
using  both  phenotypic  (carbohydrate  fermentation  pattern,  enzymatic  activity  pattern,  PAGE, 
antibiotic resistance profile) and genotypic (species-specific PCR, PFGE) methods, were provided in 
the application for further assessment. The Panel notes that the use of species-specific PCR as unique 
molecular  technique  is  insufficient  to  ensure  the  correct  assignation  of  the  species  identity,  and 
considers that the strain L. rhamnosus LR04 is not sufficiently characterised.  
For  L.  plantarum  LP02  a  culture  collection  number  from  the  BCCM/LMG,  LMG  P-21020,  was 
provided. Data on the identification and characterisation of L. plantarum LP02 at species and strain 
level, by using both phenotypic (carbohydrate fermentation pattern, enzymatic activity pattern, PAGE, 
antibiotic resistance profile) and genotypic (species-specific PCR, PFGE) methods, were provided in 
the application for further assessment and in the accompanying references (Del Piano et al., 2010). 
The Panel notes that the use of species-specific PCR as unique molecular technique is insufficient to 
ensure the correct assignation of the species identity, and considers that the strain L. plantarum LP02 
is not sufficiently characterised.  
From the references provided, the Panel assumes that the fructo-oligosaccharides (FOS) are obtained 
from sucrose. They are prepared by enzymatic elongation of sucrose, and consist of a mixture of 
kestose (glucose-fructose-fructose, GF2), nystose (GF3) and fructosylnystose (GF4), with an average 
degree  of  polymerisation  (DPav)  of  3.6,  and  are  sometimes  referred  to  as  short-chain  fructo-
oligosaccharides. FOS from sucrose differ from natural fructans by degree of polymerisation (DP) 
(only 10 % of native chicory inulin have a DP between 2 and 5) (Roberfroid, 2007), and differ from 
oligofructoses prepared by inulin hydrolysis (DP from 2 to 7, DPav 4) by the presence of a glucose 
moiety.  
The  Panel  considers  that  the  food  constituent,  a  combination  of  B.  animalis  subsp.  lactis  BS01, 
L. rhamnosus LR04, L. plantarum LP02 and short-chain fructo-oligosaccharides, which is the subject 
of the health claim, is not sufficiently characterised. 
The  Panel  concludes  that  a  cause  and  effect  relationship  cannot  be  established  between  the 
consumption of a combination of B. animalis subsp. lactis BS01, L. rhamnosus LR04, L. plantarum 
LP02 and short-chain fructo-oligosaccharides and the claimed effect considered in this section. 
1.5.  A  combination  of  Lactobacillus  acidophilus  LA02  and  Lactobacillus  plantarum  LP01 
(ID 2944) 
The  food  constituent  that  is  the  subject  of  the  health  claim  is  a  combination  of  Lactobacillus 
acidophilus LA02 and Lactobacillus plantarum LP01 related to the following claimed effect: “relief 
of abdominal discomfort and pain”.  
For L. acidophilus LA02 a culture collection number from the DSMZ, DSM 21717, was provided. 
Data on the identification and characterisation of L. acidophilus LA02 at species and strain level, by Health claims related to non-characterised microorganisms (further assessment) 
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using  both  phenotypic  (enzymatic  activity  pattern,  carbohydrate  fermentation  profile,  PAGE, 
antibiotic resistance profiles) and genotypic (species-specific PCR, PFGE) methods, were provided in 
the application for further assessment. The Panel notes that the use of species-specific PCR as unique 
molecular  technique  is  insufficient  to  ensure  the  correct  assignation  of  the  species  identity,  and 
considers that the strain L. acidophilus LA02 is not sufficiently characterised.  
For  L.  plantarum  LP01  a  culture  collection  number  from  the  BCCM/LMG,  LMG  P-21021,  was 
provided. Data on the identification and characterisation of L. plantarum LP01 at species and strain 
level, by using both phenotypic (enzymatic activity pattern, carbohydrate fermentation profile, PAGE, 
antibiotic resistance profiles) and genotypic (species-specific PCR, PFGE) methods, were provided in 
the application for further assessment and in the accompanying references (Del Piano et al., 2010). 
The Panel notes that the use of species-specific PCR as unique molecular technique is insufficient to 
ensure the correct assignation of the species identity, and considers that the strain L. plantarum LP01 
is not sufficiently characterised.  
The  Panel  considers  that  the  food  constituent,  a  combination  of  L.  acidophilus  LA02  and 
L. plantarum LP01, which is the subject of the health claim, is not sufficiently characterised. 
The  Panel  concludes  that  a  cause  and  effect  relationship  cannot  be  established  between  the 
consumption of a combination of L. acidophilus LA02 and L. plantarum LP01 and the claimed effect 
considered in this section. 
1.6.  Lactobacillus plantarum LP01 (ID 2965) 
The food constituent that is the subject of the health claim is Lactobacillus plantarum LP01 related to 
the following claimed effect: “intestinal mobility”.  
A  culture  collection  number  from  the  BCCM/LMG,  LMG  P-21021,  was  provided.  Data  on  the 
identification and characterisation of L. plantarum LP01 at species and strain level, by using both 
phenotypic (enzymatic activity pattern, carbohydrate fermentation profile, PAGE, antibiotic resistance 
profiles) and genotypic (species-specific PCR, PFGE) methods, were provided in the application for 
further assessment and in the accompanying references (Del Piano et al., 2010). The Panel notes that 
the use of species-specific PCR as unique molecular technique is insufficient to ensure the correct 
assignation of the species identity. 
The Panel considers that the food constituent, L. plantarum LP01, which is the subject of the health 
claim, is not sufficiently characterised. 
The  Panel  concludes  that  a  cause  and  effect  relationship  cannot  be  established  between  the 
consumption of L. plantarum LP01 and the claimed effect considered in this section. 
1.7.  Lactobacillus rhamnosus LR04 (ID 2968, 2969) 
The food constituent that is the subject of the health claims is Lactobacillus rhamnosus LR04 related 
to the following claimed effect: “balancing intestinal flora, improves skin, scalp and hair health” (ID 
2968) and “reduce the daily number of bowel movements” (ID 2969).  
A culture collection number from the DSMZ, DSM 16605, was provided. Data on the identification 
and characterisation of L. rhamnosus LR04 at species and strain level, by using both phenotypic 
(carbohydrate fermentation pattern, enzymatic activity pattern, PAGE, antibiotic resistance profile) 
and genotypic (species-specific PCR, PFGE) methods, were provided in the application for further 
assessment and in the accompanying annexes. The Panel notes that the use of species-specific PCR as 
unique molecular technique is insufficient to ensure the correct assignation of the species identity. Health claims related to non-characterised microorganisms (further assessment) 
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The Panel considers that the food constituent, L. rhamnosus LR04, which is the subject of the health 
claims, is not sufficiently characterised. 
The  Panel  concludes  that  a  cause  and  effect  relationship  cannot  be  established  between  the 
consumption of L. rhamnosus LR04 and the claimed effects considered in this section. 
1.8.  Bifidobacterium adolescentis BA02 (ID 3035) 
The food constituent that is the subject of the health claim is Bifidobacterium adolescentis BA02 
related to the following claimed effect: “intestinal motility”. 
A culture collection number from the DSMZ, DSM 17103, was provided. Data on the identification 
and characterisation of B. adolescentis BA02 at species and strain level, by using both phenotypic 
(carbohydrate fermentation pattern, enzymatic activity pattern, PAGE, antibiotic resistance profile) 
and genotypic (species-specific PCR, PFGE) methods, were provided in the application for further 
assessment and in the accompanying annexes. The Panel notes that the use of species-specific PCR as 
unique molecular technique is insufficient to ensure the correct assignation of the species identity.  
The Panel considers that the food constituent, B. adolescentis BA02, which is the subject of the health 
claim, is not sufficiently characterised. 
The  Panel  concludes  that  a  cause  and  effect  relationship  cannot  be  established  between  the 
consumption of B. adolescentis BA02 and the claimed effect considered in this section. 
1.9.  A combination of Bifidobacterium animalis subsp. lactis BS01, Lactobacillus rhamnosus 
LR04,  Lactobacillus  rhamnosus  LR05,  Lactobacillus  plantarum  LP01  and Lactobacillus 
plantarum  LP02  and  short-chain  fructo-oligosaccharides  or  galacto-oligosaccharides 
(ID 3047) 
The food constituent that is the subject of the health claim is a combination of Bifidobacterium lactis 
BS01,  Lactobacillus  rhamnosus  LR04,  Lactobacillus  rhamnosus  LR05,  Lactobacillus  plantarum 
LP01,  Lactobacillus  plantarum  LP02  and  short-chain  fructo-oligosaccharides  or  galacto-
oligosaccharides  related  to  the  following  claimed  effect:  “defence  against  upper  respiratory  tract 
infections”.  
For B. lactis BS01, hereafter B. animalis subsp. lactis BS01, since the species B. lactis has been 
reclassified as B. animalis subsp. lactis (Masco et al., 2004), a culture collection number from the 
BCCM/LMG,  LMG  P-21384,  was  provided.  Data  on  the  identification  and  characterisation  of 
B. animalis  subsp.  lactis  BS01  at  species  and  strain  level,  by  using  both  phenotypic  (enzymatic 
activity  pattern,  carbohydrate  fermentation  profile,  PAGE,  antibiotic  resistance  profiles)  and 
genotypic  (species-specific  PCR,  Rep-PCR,  MLST  and  genome  sequencing  [publicly available at 
genbank, Project ID 59607]) methods, were provided in the application for further assessment and in 
the  accompanying  references  (Del  Piano  et  al.,  2010).  The  Panel  considers  that  the  strain 
Bifidobacterium animalis subsp. lactis BS01 is sufficiently characterised. 
For L. rhamnosus LR04 a culture collection number from the DSMZ, DSM 16605, was provided. 
Data on the identification and characterisation of L. rhamnosus LR04 at species and strain level, by 
using  both  phenotypic  (carbohydrate  fermentation  pattern,  enzymatic  activity  pattern,  PAGE, 
antibiotic resistance profile) and genotypic (species-specific PCR, PFGE) methods, were provided in 
the application for further assessment. The Panel notes that the use of species-specific PCR as unique 
molecular  technique  is  insufficient  to  ensure  the  correct  assignation  of  the  species  identity,  and 
considers that the strain L. rhamnosus LR04 is not sufficiently characterised. Health claims related to non-characterised microorganisms (further assessment) 
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For L. rhamnosus LR05 a culture collection number from the DSMZ, DSM 19739, was provided. 
Data on the identification and characterisation of L. rhamnosus LR05 at species and strain level, by 
using  both  phenotypic  (carbohydrate  fermentation  pattern,  enzymatic  activity  profile,  PAGE, 
antibiotic resistance profile) and genotypic (species-specific PCR, PFGE) methods, were provided in 
the application for further assessment. The Panel notes that the use of species-specific PCR as unique 
molecular  technique  is  insufficient  to  ensure  the  correct  assignation  of  the  species  identity,  and 
considers that the strain L. rhamnosus LR05 is not sufficiently characterised.  
For  L.  plantarum  LP01  a  culture  collection  number  from  the  BCCM/LMG,  LMG  P-21021,  was 
provided. Data on the identification and characterisation of L. plantarum LP01 at species and strain 
level, by using both phenotypic (enzymatic activity pattern, carbohydrate fermentation profile, PAGE, 
antibiotic resistance profiles) and genotypic (species-specific PCR, PFGE) methods, were provided in 
the application for further assessment and in the accompanying references (Del Piano et al., 2010). 
The Panel notes that the use of species-specific PCR as unique molecular technique is insufficient to 
ensure the correct assignation of the species identity, and considers that the strain L. plantarum LP01 
is not sufficiently characterised.  
For  L.  plantarum  LP02  a  culture  collection  number  from  the  BCCM/LMG,  LMG  P-21020,  was 
provided. Data on the identification and characterisation of L. plantarum LP02 at species and strain 
level, by using both phenotypic (carbohydrate fermentation pattern, enzymatic activity pattern, PAGE, 
antibiotic resistance profile) and genotypic (species-specific PCR, PFGE) methods, were provided in 
the application for further assessment and in the accompanying references (Del Piano et al., 2010). 
The Panel notes that the use of species-specific PCR as unique molecular technique is insufficient to 
ensure the correct assignation of the species identity, and considers that the strain L. plantarum LP02 
is not sufficiently characterised. 
From the references provided, the Panel assumes that the fructo-oligosaccharides (FOS) are obtained 
from sucrose. They are prepared by enzymatic elongation of sucrose, and consist of a mixture of 
kestose (glucose-fructose-fructose, GF2), nystose (GF3) and fructosylnystose (GF4), with an average 
degree  of  polymerisation  (DPav)  of  3.6,  and  are  sometimes  referred  to  as  short-chain  fructo-
oligosaccharides. FOS from sucrose differ from natural fructans by degree of polymerisation (DP) 
(only 10 % of native chicory inulin have a DP between 2 and 5) (Roberfroid, 2007), and differ from 
oligofructoses prepared by inulin hydrolysis (DP from 2 to 7, DPav 4) by the presence of a glucose 
moiety.  
Galacto-oligosaccharides (GOS) are formed by enzymatic treatment of lactose with β-galactosidases 
with transgalactosylation activities to produce several oligomers of different chain lengths. In the 
reaction 4’- or 6’-galactosyl-lactose, longer oligosaccharides, transgalactosylated disaccharides and 
non-reducing  oligosaccharides  are  formed.  The  microbial  source  of  β-galactosidase  affects  the 
utilisation  of  the  substrate  by  gut  bacteria  (Depeint  et  al.,  2008). The Panel notes that there are 
different GOS with different chain lengths.  
The Panel considers that the food constituent, a combination of B. animalis subsp. lactis BS01, L. 
rhamnosus  LR04,  L.  rhamnosus  LR05,  L.  plantarum  LP01,  L.  plantarum  LP02,  and  short-chain 
fructo-oligosaccharides or galacto-oligosaccharides, which is the subject of the health claim, is not 
sufficiently characterised. 
The  Panel  concludes  that  a  cause  and  effect  relationship  cannot  be  established  between  the 
consumption of a combination of B. animalis subsp. lactis BS01, L. rhamnosus LR04, L. rhamnosus 
LR05, L. plantarum LP01, L. plantarum LP02 and short-chain fructo-oligosaccharides or galacto-
oligosaccharides and the claimed effect considered in this section. Health claims related to non-characterised microorganisms (further assessment) 
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1.10.  Bifidobacterium longum W11 (ID 3056) 
The food constituent that is the subject of the health claim is Bifidobacterium longum W11 related to 
the following claimed effect: “relief of abdominal discomfort and bloating”.  
A  culture  collection  number  from  the  BCCM/LMG,  LMG  P-21586,  was  provided.  Data  on  the 
identification  and  characterisation  of  B.  longum  W11  at  species  and  strain  level,  by  using  both 
phenotypic (enzymatic activity pattern, carbohydrate fermentation profile, PAGE, antibiotic resistance 
profile) and genotypic (species-specific PCR, PFGE) methods, were provided in the application for 
further assessment and in the accompanying references (Morelli, 2003; No authors listed, 2011). The 
Panel notes that the use of species-specific PCR as unique molecular technique is insufficient to 
ensure the correct assignation of the species identity.  
The Panel considers that the food constituent, B. longum W11, which is the subject of the health 
claim, is not sufficiently characterised. 
The  Panel  concludes  that  a  cause  and  effect  relationship  cannot  be  established  between  the 
consumption of B. longum W11 and the claimed effect considered in this section. 
1.11.  A combination of Bifidobacterium animalis subsp. lactis BS01, Lactobacillus rhamnosus 
LR04, Lactobacillus plantarum LP02, lactoferrin and short-chain fructo-oligosaccharides 
(ID 3059) 
The food constituent that is the subject of the health claim is a combination of Bifidobacterium lactis 
BS01,  Lactobacillus rhamnosus  LR04,  Lactobacillus  plantarum  LP02,  lactoferrin  and  short-chain 
fructo-oligosaccharides related to the following claimed effect: “defence against upper respiratory 
tract infections”.  
For B. lactis BS01, hereafter B. animalis subsp. lactis BS01, since the species B. lactis has been 
reclassified as B. animalis subsp. lactis (Masco et al., 2004), a culture collection number from the 
BCCM/LMG,  LMG  P-21384,  was  provided.  Data  on  the  identification  and  characterisation  of 
B. lactis  BS01  at  species  and  strain  level,  by  using  both  phenotypic  (enzymatic  activity  pattern, 
carbohydrate  fermentation  profile,  PAGE,  antibiotic  resistance  profiles)  and  genotypic  (species-
specific PCR, Rep-PCR, MLST and genome sequencing [publicly available at genbank, Project ID 
59607]) methods, were provided in the application for further assessment and in the accompanying 
references (Del Piano et al., 2010). The Panel considers that the strain B. animalis subsp. lactis BS01 
is sufficiently characterised. 
For L. rhamnosus LR04 a culture collection number from the DSMZ, DSM 16605, was provided. 
Data on the identification and characterisation of L. rhamnosus LR04 at species and strain level, by 
using  both  phenotypic  (carbohydrate  fermentation  pattern,  enzymatic  activity  pattern,  PAGE, 
antibiotic resistance profile) and genotypic (species-specific PCR, PFGE) methods, were provided in 
the application for further assessment. The Panel notes that the use of species-specific PCR as unique 
molecular  technique  is  insufficient  to  ensure  the  correct  assignation  of  the  species  identity,  and 
considers that the strain L. rhamnosus LR04 is not sufficiently characterised.  
For  L.  plantarum  LP02  a  culture  collection  number  from  the  BCCM/LMG,  LMG  P-21020,  was 
provided. Data on the identification and characterisation of L. plantarum LP02 at species and strain 
level, by using both phenotypic (carbohydrate fermentation pattern, enzymatic activity pattern, PAGE, 
antibiotic resistance profile) and genotypic (species-specific PCR, PFGE) methods, were provided in 
the application for further assessment and in the accompanying references (Del Piano et al., 2010). 
The Panel notes that the use of species-specific PCR as unique molecular technique is insufficient to 
ensure the correct assignation of the species identity, and considers that the strain L. plantarum LP02 
is not sufficiently characterised. Health claims related to non-characterised microorganisms (further assessment) 
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Lactoferrin is a globular glycoprotein with a molecular mass of approximately 77 kDa which occurs 
naturally in cow’s milk. The tertiary structure of this glycoprotein has two iron-binding sites, which 
enables it to bind two Fe
3+ ions per molecule of protein.  
From the references provided, the Panel assumes that the fructo-oligosaccharides (FOS) are obtained 
from sucrose. They are prepared by enzymatic elongation of sucrose, and consist of a mixture of 
kestose (glucose-fructose-fructose, GF2), nystose (GF3) and fructosylnystose (GF4), with an average 
degree  of  polymerisation  (DPav)  of  3.6,  and  are  sometimes  referred  to  as  short-chain  fructo-
oligosaccharides. FOS from sucrose differ from natural fructans by degree of polymerisation (DP) 
(only 10 % of native chicory inulin have a DP between 2 and 5) (Roberfroid, 2007), and differ from 
oligofructoses prepared by inulin hydrolysis (DP from 2 to 7, DPav 4) by the presence of a glucose 
moiety.  
The Panel considers that the food constituent, a combination of B. animalis subsp. lactis BS01, L. 
rhamnosus LR04, L. plantarum LP02, lactoferrin and short-chain fructo-oligosaccharides, which is 
the subject of the health claim, is not sufficiently characterised. 
The  Panel  concludes  that  a  cause  and  effect  relationship  cannot  be  established  between  the 
consumption of B. animalis subsp. lactis BS01, L. rhamnosus LR04, L. plantarum LP02, lactoferrin 
and short-chain fructo-oligosaccharides and the claimed effect considered in this section. 
CONCLUSIONS  
On the basis of the data presented, the Panel concludes that: 
  The following food constituents are not sufficiently characterised: 
-  Bifidobacterium breve BR03 related to the following claimed effect: “intestinal mobility” 
(ID 2936). 
-  Bifidobacterium  longum  BL03  related  to  the  following  claimed  effect:  “intestinal 
mobility” (ID 2937). 
-  A combination of Bifidobacterium breve BR03 and Lactobacillus plantarum LP01 related 
to  the  following  claimed  effect:  “reducing  gastrointestinal  discomfort  associated  with 
increased transit time” (ID 2938). 
-  A combination of Bifidobacterium animalis subsp. lactis BS01, Lactobacillus rhamnosus 
LR04, Lactobacillus plantarum LP02, and short-chain fructo-oligosaccharides related to 
the  following  claimed  effect:  “defence  against  upper  respiratory  tract  infections” 
(ID 2941). 
-  A  combination  of  Lactobacillus  acidophilus  LA02  and  Lactobacillus  plantarum  LP01 
related  to  the  following  claimed  effect:  “relief  of  abdominal  discomfort  and  pain” 
(ID 2944). 
-  Lactobacillus  plantarum  LP01  related  to  the  following  claimed  effect:  “intestinal 
mobility” (ID 2965). 
-  Lactobacillus  rhamnosus  LR04  related  to  the  following  claimed  effect:  “balancing 
intestinal flora, improves skin, scalp and hair  health” (ID 2968) and “reduce the daily 
number of bowel movements” (ID 2969). 
-  Bifidobacterium  adolescentis  BA02  (ID  3035)  related  to  the  following  claimed  effect: 
“intestinal motility”. 
-  A combination of Bifidobacterium animalis subsp. lactis BS01, Lactobacillus rhamnosus 
LR04,  Lactobacillus  rhamnosus  LR05,  Lactobacillus  plantarum  LP01,  Lactobacillus Health claims related to non-characterised microorganisms (further assessment) 
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plantarum  LP02  and  short-chain  fructo-oligosaccharides  or  galacto-oligosaccharides 
related to the following claimed effect: “defence against upper respiratory tract infections” 
(ID 3047). 
-  Bifidobacterium longum W11 related to the following claimed effect: “relief of abdominal 
discomfort and bloating” (ID 3056). 
-  A combination of Bifidobacterium animalis subsp. lactis BS01, Lactobacillus rhamnosus 
LR04, Lactobacillus plantarum LP02, lactoferrin and short-chain fructo-oligosaccharides 
related to the following claimed effect: “defence against upper respiratory tract infections” 
(ID 3059). 
  A cause and effect relationship cannot be established between the consumption of the food 
constituents, which are the subject of this opinion, and the proposed claimed effects. 
DOCUMENTATION PROVIDED TO EFSA 
Health  claims  pursuant  to  Article  13  of  Regulation  (EC)  No  1924/2006  for  further  assessment 
(No: EFSA-Q-2012-00173,  EFSA-Q-2012-00174,  EFSA-Q-2012-00175,  EFSA-Q-2012-00177, 
EFSA-Q-2012-00179,  EFSA-Q-2012-00193,  EFSA-Q-2012-00196,  EFSA-Q-2012-00197,  EFSA-Q-
2012-00206,  EFSA-Q-2012-00207,  EFSA-Q-2012-00209,  EFSA-Q-2012-00210).  The  scientific 
substantiation is based on the information provided by the competent Authority of Italy for further 
assessment of this claim (available at: http://www.efsa.europa.eu/en/topics/topic/article13.htm). 
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APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The  Regulation  1924/2006  on  nutrition  and  health  claims  made  on  foods
6  (hereinafter  "the 
Regulation") entered into force on 19
th January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health".  
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a)  the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b)  psychological and behavioural functions; or 
c)  without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be:  
(i)  based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3).  
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
7  
Foods are commonly involved in many different functions
8 of the body, and for one single food many 
health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to 
a single food is scientifically pertinent.  
                                                       
6  OJ L12, 18/01/2007 
7  The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
8  The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).  Health claims related to non-characterised microorganisms (further assessment) 
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It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect.  
SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific 
data, and by weighing the evidence, and shall demonstrate the extent to which: 
(a)  the claimed effect of the food is beneficial for human health, 
(b)  a cause and effect relationship is established between consumption of the food and the 
claimed  effect  in  humans  (such  as:  the  strength,  consistency,  specificity,  dose-
response, and biological plausibility of the relationship), 
(c)  the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d)  the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of 
the  application  for  authorisation  of  health  claims  consistent  criteria  for  the  potential  sources  of 
scientific  data.  Such  sources  may  not  be  available  for  all  health  claims.  Nevertheless  it  will  be 
relevant and important that EFSA comments on the availability and quality of such data in order to 
allow the regulator to judge and make a risk management decision about the acceptability of health 
claims included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not 
enough to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. 
Moreover, the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially 
affect identified functions in the body in a way which is relevant to health. Although an appreciation 
of the beneficial effect in relation to the nutritional status of the European population may be of 
interest, the presence or absence of the actual need for a nutrient or other substance with nutritional or 
physiological effect for that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic 
or cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to Health claims related to non-characterised microorganisms (further assessment) 
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describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of 
the body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function  of  the  joints"  may  not  sufficiently  do  so,  whereas  a  claim  such  as  "Substance  X  helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various  functions  of  the  joints  is  described  or  referred  to  contrary  to  the  latter  example  which 
specifies this by using the word "flexibility". 
The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore 
be specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings 
should  be  avoided.  To  this  end,  wordings  like  "strengthens  your  natural  defences"  or  "contain 
antioxidants"  should  be  considered  as  well  as  "may"  or  "might"  as  opposed  to  words  like 
"contributes", "aids" or "helps".  
In  addition,  for  functions  affected  by  a  large  number  of  dietary  factors  it  should  be  considered 
whether  wordings  such  as  "indispensable",  "necessary",  "essential"  and  "important"  reflects  the 
strength of the scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects:  
  Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
  Whether  the  beneficial  effect  of  the  food  on  the  function  is  substantiated  by  generally 
accepted scientific evidence by taking into account the totality of the available scientific data, 
and by weighing the evidence. In this context EFSA is invited to comment on the nature and 
quality of the totality of the evidence provided according to consistent criteria. 
  The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent.  
In addition, EFSA should consider the claimed effect on the function, and provide advice on the 
extent to which: Health claims related to non-characterised microorganisms (further assessment) 
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  the claimed effect of the food in the identified function is beneficial. 
  a cause and effect relationship has been established between consumption of the food and the 
claimed effect in humans and whether the magnitude of the effect is related to the quantity 
consumed. 
  where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
  the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
  the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
  on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. Health claims related to non-characterised microorganisms (further assessment) 
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APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of  the  food/food  constituent,  a  positive  assessment  of  its  safety,  nor  a  decision  on  whether  the 
food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
 
 
 Health claims related to non-characterised microorganisms (further assessment) 
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APPENDIX C 
Table 1. Health claims related to non-characterised microorganisms, including conditions of use, as proposed in the framework of further assessment. 
ID  Food or Food constituent  Health Relationship  Proposed wording 
2936  Bifidobacterium breve BR 03   The  intake  of  Bifidobacterium  breve  BR  03  is  able  to  help  restore  a 
physiological intestinal motility by reducing the transit time in healthy adult 
subjects with mild to moderately decreased peristalsis and altered bowel habits 
(number of weekly bowel movements less than 7 and evacuation disorders as 
straining at evacuation, hard faeces or anal itching, burning, or pain during or 
after defecation). This beneficial effect was particularly evident in the elderly 
enrolled in the efficacy study.  
Contributes  to  reduce  the  intestinal 
transit  time,  especially  in  adults  or 
elderly reporting less than one bowel 
movement  per  day,  and  evacuation 
disorders.  
Conditions of use 
The target population is represented by adults, and especially the elderly with an impaired peristalsis and altered bowel habits (number of weekly bowel 
movements < 7, evacuation disorders as straining at evacuation, hard faeces or anal itching, burning, or pain during or after defecation). A relatively reduced 
peristalsis is pretty normal in adult population after 50 years of age, and especially in the elderly. However, it is well known that about 12% of world-wide 
adult individuals suffer from impaired intestinal peristalsis. In other words, even if the frequency of reduced intestinal motility is higher in the elderly, also a 
relevant percentage of adult population reports a moderately suboptimal intestinal transit (Heaton KW. et al. Defecation frequency and timing, and stool 
form in the general population: a prospective study. Gut, 1992; 33:818-824). Subjects with a slightly impaired intestinal motility function (i.e. less frequent 
evacuations, unsatisfactory sensation of complete emptying) could take advantage from the intake of Bifidobacterium breve BR 03 for at least 15 days at a 
concentration of 10 billion viable cells/day. The microorganism Bifidobacterium breve BR 03, which is the subject of the present claim, should be 
consumed for at least 15 days at a concentration of 10 billion viable cells/day in order to achieve the positive health effect. The subjects are normally 
directed to take the probiotic once a day, preferably early in the morning or late in the evening in order to be on an empty stomach. It is reasonable to 
assume that this quantity could be consumed as part of a balanced diet, especially if formulated in the form of a food supplement.  
There are no specific restrictions of use. The absence of any side effect or complication was noted throughout the course of the studies in subjects taking 5 
or 10 billion viable cells/day. It is well known that probiotics, notably the strains belonging to a species with a Qualified Presumption of Safety (QPS), could 
be consumed in amounts up to 1011-1012 viable cells/day without any health risk. There are many products on the market containing up to 500 billion of 
viable cells per dose of a probiotic belonging to a QPS species. No health risk has ever been reported so far. The species Bifidobacterium breve is included 
in the QPS list.  
The general recommendation is to take probiotics on an empty stomach and to rehydrate the product using about half glass of cold water or other non-
carbonated drinks at temperatures not exceeding 37°C. There are no other specific directions for preparation and/or use.  
 Health claims related to non-characterised microorganisms (further assessment) 
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ID  Food or Food constituent  Health Relationship  Proposed wording 
2937  Bifidobacterium longum BL 03  The intake of Bifidobacterium longum BL 03 is able to help restore a 
physiological intestinal motility by reducing the transit time in healthy 
adult subjects with mild to moderately decreased peristalsis and altered 
bowel habits (number of weekly bowel movements less than 7 and 
evacuation disorders as straining at evacuation, hard faeces or anal itching, 
burning, or pain during or after defecation). This beneficial effect was 
particularly evident in the elderly enrolled in the efficacy study.  
 
Contributes to reduce the intestinal transit 
time,  especially  in  adults  or  elderly 
reporting  less  than  one  bowel  movement 
per day, and evacuation disorders.  
Conditions of use 
The target population is represented by adults, and especially the elderly with an impaired peristalsis and altered bowel habits (number of weekly bowel 
movements < 7, evacuation disorders as straining at evacuation, hard faeces or anal itching, burning, or pain during or after defecation). A relatively reduced 
peristalsis is pretty normal in adult population after 50 years of age, and especially in the elderly. However, it is well known that about 12% of world-wide 
adult individuals suffer from impaired intestinal peristalsis. In other words, even if the frequency of reduced intestinal motility is higher in the elderly, also a 
relevant percentage of adult population reports a moderately suboptimal intestinal transit (Heaton KW. et al. Defecation frequency and timing, and stool 
form in the general population: a prospective study. Gut, 1992; 33:818-824).  
Subjects with a slightly impaired intestinal motility function (i.e. less frequent bowel movements, unsatisfactory sensation of complete emptying) could take 
advantage from the intake of Bifidobacterium longum BL 03 for at least 15 days at a concentration of 10 billion viable cells/day  
The microorganism Bifidobacterium longum BL 03, which is the subject of the present claim, should be consumed for at least 15 days at a concentration of 
10 billion viable cells/day in order to achieve the positive health effect. The subjects are normally directed to take the probiotic once a day, preferably early 
in the morning or late in the evening in order to be on an empty stomach. It is reasonable to assume that this quantity could be consumed as part of a 
balanced diet, especially if formulated in the form of a food supplement.  
There are no specific restrictions of use. The absence of any side effect or complication was noted throughout the course of the study in subjects taking 10 
billion viable cells/day. It is well known that probiotics, notably the strains belonging to a species with a Qualified Presumption of Safety (QPS), could be 
consumed in amounts up to 1011-1012 viable cells/day without any health risk. There are many products on the market containing up to 500 billion of 
viable cells per dose of a probiotic belonging to a QPS species. No health risk has ever been reported so far. The species Bifidobacterium longum is 
included in the QPS list.  
The general recommendation is to take probiotics on an empty stomach and to rehydrate the product using about half glass of cold water or other non-
carbonated drinks at temperatures not exceeding 37°C. There are no other specific directions for preparation and/or use.  
 Health claims related to non-characterised microorganisms (further assessment) 
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ID  Food or Food constituent  Health Relationship  Proposed wording 
2938  A combination of the two 
probiotic strains 
Bifidobacterium breve BR 03 
and Lactobacillus plantarum LP 
01 
The  intake  of  a  combination  of  Bifidobacterium  breve  BR  03  and 
Lactobacillus  plantarum  LP  01  is  able  to  relieve  symptoms  typically 
associated  with  Irritable  Bowel  Syndrome  (IBS),  especially  abdominal 
discomfort, and help restore a physiological intestinal motility by reducing 
the transit time in healthy adult subjects with mild to moderately decreased 
peristalsis and altered bowel habits (number of weekly bowel movements 
less than 7 and evacuation disorders as straining at evacuation, hard faeces 
or anal itching, burning, or pain during or after defecation). This beneficial 
effect was particularly evident both in adults suffering from IBS enrolled 
in  the  first  efficacy  study  (Saggioro  A.  Journal  of  Clinical 
Gastroenterology, 2004) and in adults with slightly to moderately impaired 
intestinal  motility  involved  in  the  second  study  (Del  Piano  M.  et  al. 
Journal of Clinical Gastroenterology, 2010 (b)). It is important to note that 
most subjects suffering from IBS report also a reduced number of weekly 
bowel movements.  
Reduces  intestinal  discomfort  and 
abdominal  bloating  in  Irritable  Bowel 
Syndrome  and  in  functional  disorders  of 
the  gut,  also  contributing  to  restore  and 
maintain a physiological intestinal transit.  
Conditions of use 
The target population is represented by adults suffering either from Irritable Bowel Syndrome or from mild to moderately reduced intestinal motility, also if 
associated with abdominal bloating. Some symptoms are common to both conditions taken into account in the two studies. Abdominal bloating, abdominal 
discomfort and an impaired peristalsis are the best examples.  
The combination of Bifidobacterium breve BR 03 and Lactobacillus plantarum LP 01, which is the subject of the present claim, should be consumed for at 
least 28 days at a concentration of 2.5 to 5 billion viable cells of each strain/day in order to achieve the positive health effect. The most recent efficacy study, 
involving the higher number of subjects, demonstrated the efficacy of such combination given at 2.5 billion viable cells of each strain/day. The subjects are 
normally directed to take the probiotic once a day, preferably early in the morning or late in the evening in order to be on an empty stomach. It is reasonable 
to assume that this quantity could be consumed as part of a balanced diet, especially if formulated in the form of a food supplement.  
There are no specific restrictions of use. The absence of any side effect or complication was noted throughout the course of the studies in subjects taking 2.5 
or 5 billion viable cells of each strain/day. It is well known that probiotics, notably the strains belonging to a species with a Qualified Presumption of Safety 
(QPS), could be consumed in amounts up to 1011-1012 viable cells/day without any health risk. There are many products on the market containing up to 
500 billion of viable cells per dose of a probiotic belonging to a QPS species. No health risk has ever been reported so far. The species Bifidobacterium 
breve and Lactobacillus plantarum are included in the QPS list.  
The general recommendation is to take probiotics on an empty stomach and to rehydrate the product using about half glass of cold water or other non-
carbonated drinks at temperatures not exceeding 37°C. There are no other specific directions for preparation and/or use.  Health claims related to non-characterised microorganisms (further assessment) 
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ID  Food or Food constituent  Health Relationship  Proposed wording 
2941  A  combination  of  the  three 
probiotic  strains 
Bifidobacterium  lactis  BS  01, 
Lactobacillus rhamnosus LR 04 
and Lactobacillus plantarum LP 
02. Such combination of strains 
should  be  associated  with  3 
grams  of  short-chain  fructo-
oligosaccharides  (scFOS),  used 
for their prebiotic properties.  
 
The  intake  of  a  combination  of  Bifidobacterium  lactis  BS  01, 
Lactobacillus rhamnosus LR 04 and Lactobacillus plantarum LP 02 is 
able to reduce the incidence, severity and duration of Acute Respiratory 
Infections  (ARI),  especially  during  the  cold  season.  The  efficacy  was 
demonstrated  with  the  three  strains  in  association  with  3  grams  of  the 
prebiotic  fibre  short-chain  fructo-oligosaccharides  (scFOS),  specifically 
selected  to  enhance  the  colonization  of  the  gut  by  the  probiotic 
component.  
Contributes  to  reduce  the  incidence, 
duration  and  severity  of  symptoms  of 
Acute Respiratory Infections, including flu 
and  influenza-like  illnesses,  especially 
during the cold season. 
Conditions of use 
The target population is represented by normal adults. As a matter of fact, subjects enrolled in the placebo group are fully representative of the general 
population and the overall incidence of ARI in such group reflected the incidence of ARI in the general population. Subjects were completely healthy at 
enrolment without any symptom.  
Adult subjects could take advantage from the intake of B. lactis BS 01, L. rhamnosus LR 04 and L. plantarum LP 02 for at least 90 days (or, in any case, till 
the end of the cold season) at a concentration of 10 billion viable cells of each strain/day  
The combination of B. lactis BS 01, L. rhamnosus LR 04 and L. plantarum LP 02, which is the subject of the present claim, should be consumed for at least 
90 days (or, in any case, till the end of the cold season) at a concentration of 10 billion viable cells of each strain/day in order to achieve the positive health 
effect. The subjects are directed to take the probiotic once a day, preferably early in the morning or late in the evening in order to be on an empty stomach. It 
is reasonable to assume that this quantity could be consumed as part of a balanced diet, especially if formulated in the form of a food supplement.  
There are no specific restrictions of use. The absence of any side effect or complication was noted throughout the course of the studies in subjects taking 10 
billion viable cells of each strain/day for 90 consecutive days. It is well known that probiotics, notably the strains belonging to a species with a Qualified 
Presumption of Safety (QPS), could be consumed in amounts up to 1011-1012 viable cells/day without any health risk. There are many products on the 
market containing up to 500 billion of viable cells per dose of a probiotic belonging to a QPS species. No health risk has ever been reported so far. The 
species Bifidobacterium lactis, Lactobacillus rhamnosus and Lactobacillus plantarum are included in the QPS list.  
The general recommendation is to take probiotics on an empty stomach and to rehydrate the product using about half glass of cold water or other non-
carbonated drinks at temperatures not exceeding 37°C. There are no other specific directions for preparation and/or use.  
 Health claims related to non-characterised microorganisms (further assessment) 
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ID  Food or Food constituent  Health Relationship  Proposed wording 
2944  A  combination  of  the  two 
probiotic  strains  Lactobacillus 
acidophilus  LA  02  and 
Lactobacillus plantarum LP 01  
The intake of the combination of Lactobacillus acidophilus LA 02 and 
Lactobacillus  plantarum  LP  01  is  able  to  relieve  symptoms  typically 
associated  with  Irritable  Bowel  Syndrome  (IBS),  especially  abdominal 
discomfort  and  pain  at  different  locations.  This  beneficial  effect  was 
particularly evident in adults suffering from IBS enrolled in the efficacy 
study (Saggioro A. Journal of Clinical Gastroenterology, 2004). 
Reduces  intestinal  discomfort  and 
abdominal  bloating  in  Irritable  Bowel 
Syndrome  and  in  functional  disorders  of 
the gut.  
Conditions of use 
The target population is represented by adults suffering from Irritable Bowel Syndrome, thus reporting abdominal pain at different locations and related 
symptoms as flatulence, constipation and bloating.  
Subjects reporting IBS symptoms (i.e. abdominal pain or discomfort, generally associated with other conditions as flatulence, constipation and abdominal 
bloating) could take advantage from the intake of a combination of Lactobacillus acidophilus LA 02 and Lactobacillus plantarum LP 01 for at least 28 days 
at a concentration of 5 billion viable cells of each strain/day.  
The combination of Lactobacillus acidophilus LA 02 and Lactobacillus plantarum LP 01, which is the subject of the present claim, should be consumed for 
at least 28 days at a concentration of 5 billion viable cells of each strain/day in order to achieve the positive health effect. The subjects are normally directed 
to take the probiotic once a day, preferably early in the morning or late in the evening in order to be on an empty stomach. It is reasonable to assume that 
this quantity could be consumed as part of a balanced diet, especially if formulated in the form of a food supplement.  
There are no specific restrictions of use. The absence of any side effect or complication was noted throughout the course of the study in subjects taking 5 
billion viable cells of each strain/day. It is well known that probiotics, notably the strains belonging to a species with a Qualified Presumption of Safety 
(QPS), could be consumed in amounts up to 1011-1012 viable cells/day without any health risk. There are many products on the market containing up to 
500 billion of viable cells per dose of a probiotic belonging to a QPS species. No health risk has ever been reported so far. The species Lactobacillus 
acidophilus and Lactobacillus plantarum are included in the QPS list.  
The general recommendation is to take probiotics on an empty stomach and to rehydrate the product using about half glass of cold water or other non-
carbonated drinks at temperatures not exceeding 37°C. There are no other specific directions for preparation and/or use. 
 
 
 
 
 Health claims related to non-characterised microorganisms (further assessment) 
 
27  EFSA Journal 2012;10(8):2854 
ID  Food or Food constituent  Health Relationship  Proposed wording 
2965  Lactobacillus plantarum LP 01  The  intake  of  Lactobacillus plantarum LP 01 is able to help restore a 
physiological  intestinal  motility  by  reducing  the  transit  time  in  healthy 
adult subjects with mild to moderately decreased peristalsis and altered 
bowel  habits  (number  of  weekly  bowel  movements  less  than  7  and 
evacuation disorders as straining at evacuation, hard faeces or anal itching, 
burning,  or  pain  during  or  after defecation). This beneficial effect was 
particularly evident in the elderly enrolled in the efficacy study. 
Contributes to reduce the intestinal transit 
time,  especially  in  adults  or  elderly 
reporting  less  than  one  bowel  movement 
per day, and evacuation disorders.  
Conditions of use 
The target population is represented by adults, and especially the elderly with an impaired peristalsis and altered bowel habits (number of weekly bowel 
movements < 7, evacuation disorders as straining at evacuation, hard faeces or anal itching, burning, or pain during or after defecation). A relatively reduced 
peristalsis is pretty normal in adult population after 50 years of age, and especially in the elderly. Subjects with a slightly impaired intestinal motility 
function and altered bowel habits (i.e. less frequent bowel movements, unsatisfactory sensation of complete emptying) could take advantage from the intake 
of Lactobacillus plantarum LP 01 for at least 15 days at a concentration of 10 billion viable cells/day.  
The microorganism Lactobacillus plantarum LP 01, which is the subject of the present claim, should be consumed for at least 15 days at a concentration of 
10 billion viable cells/day in order to achieve the positive health effect. The subjects are normally directed to take the probiotic once a day, preferably early 
in the morning or late in the evening in order to be on an empty stomach. It is reasonable to assume that this quantity could be consumed as part of a 
balanced diet, especially if formulated in the form of a food supplement.  
There are no specific restrictions of use. The absence of any side effect or complication was noted throughout the course of the studies in subjects taking 5 
or 10 billion viable cells/day. It is well known that probiotics, notably the strains belonging to a species with a Qualified Presumption of Safety (QPS), could 
be consumed in amounts up to 1011-1012 viable cells/day without any health risk. There are many products on the market containing up to 500 billion of 
viable cells per dose of a probiotic belonging to a QPS species. No health risk has ever been reported so far. The species Lactobacillus plantarum is 
included in the QPS list.  
The general recommendation is to take probiotics on an empty stomach and to rehydrate the product using about half glass of cold water or other non-
carbonated drinks at temperatures not exceeding 37°C. There are no other specific directions for preparation and/or use. 
 
 
 
 Health claims related to non-characterised microorganisms (further assessment) 
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ID  Food or Food constituent  Health Relationship  Proposed wording 
2968  Lactobacillus rhamnosus LR 04  Lactobacillus rhamnosus LR 04 (DSM 16605), balancing intestinal flora, 
improves skin, scalp and hair health reducing scalp scaling. Improves gut 
absorption and bioavailability of the other components of the food 
supplements. 
An increase in stress and modern day living, which makes a consequential 
demand on the immune system, can disrupt homeostasis in the gut. 
Similarly, the direct effects of a change in dietary patterns and eating 
habits can affect overall gut function. 
Many  experimental  studies  have  found  that  probiotics  exert  specific 
effects in the intestinal lumen and on epithelial cells and immune cells 
with antiallergic potential. 
Lactobacillus  rhamnosus  LR  04  (DSM 
16605): skin and annexes health: balancing 
intestinal  flora  improves  skin,  scalp  and 
hair  health  reducing  scalp  scaling. 
Improves gut absorption and bioavailability 
of  the  other  components  of  the  food 
supplements.  
Conditions of use 
Lactobacillus rhamnosus LR 04 (DSM 16605) is used as an ingredient in a dietary supplement. Recommended intake is one tablet per day, which contains 
at least 109 cfu/day, taken preferably with breakfast in the morning. 
Is recommended to consumed it as a part of balanced and variet diet and in a healthy lifestyle. 
 
ID  Food or Food constituent  Health Relationship  Proposed wording 
2969  Lactobacillus rhamnosus LR 04  The intake of Lactobacillus rhamnosus LR 04 is able to help reduce the 
daily number of bowel movements as well as improve the consistency of 
faeces  in  elderly  subjects  reporting  chronic  diarrhea  related  to  Irritable 
Bowel Syndrome.  
Contributes to reduce the number of daily 
evacuations and improve the consistency of 
faeces in case of chronic diarrhea related to 
the  following  claimed  effect:  Irritable 
Bowel Syndrome, especially in the elderly. 
 Health claims related to non-characterised microorganisms (further assessment) 
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Conditions of use 
The target population is represented by the adults, and especially the elderly with chronic diarrhea related to the following claimed effect: Irritable Bowel 
Syndrome.  
Adult or elderly subjects with chronic diarrhea (daily number of defecations > 4 and reduced faeces consistency) could take advantage from the intake of L. 
rhamnosus LR 04 for at least 15 days at a concentration of 10 billion viable cells/day.  
The strain Lactobacillus rhamnosus LR 04, which is the subject of the present claim, should be consumed for at least 15 days at a concentration of 10 
billion viable cells/day in order to achieve the positive health effect. The subjects are directed to take the probiotic once a day, preferably early in the 
morning or late in the evening in order to be on an empty stomach. It is reasonable to assume that this quantity could be consumed as part of a balanced diet, 
especially if formulated in the form of a food supplement.  
There are no specific restrictions of use. The absence of any side effect or complication was noted throughout the course of the study in subjects taking 10 
billion viable cells /day for 15 consecutive days. It is well known that probiotics, notably the strains belonging to a species with a Qualified Presumption of 
Safety (QPS), could be consumed in amounts up to 1011-1012 viable cells/day without any health risk. There are many products on the market containing 
up to 500 billion of viable cells per dose of a probiotic belonging to a QPS species. No health risk has ever been reported so far. The species Lactobacillus 
rhamnosus is included in the QPS list.  
The general recommendation is to take probiotics on an empty stomach and to rehydrate the product using about half glass of cold water or other non-
carbonated drinks at temperatures not exceeding 37°C. There are no other specific directions for preparation and/or use.  
 
ID  Food or Food constituent  Health Relationship  Proposed wording 
3035  Bifidobacterium  adolescentis 
BA 02 
The intake of Bifidobacterium adolescentis BA 02 is able to help restore a 
physiological  intestinal  motility  by  reducing  the  transit  time  in  healthy 
adult subjects with mild to moderately decreased peristalsis and altered 
bowel  habits  (number  of  weekly  bowel  movements  less  than  7  and 
evacuation disorders as straining at evacuation, hard faeces or anal itching, 
burning,  or  pain  during  or  after defecation). This beneficial effect was 
particularly evident in the elderly enrolled in the efficacy study  
 
Contributes to reduce the intestinal transit 
time,  especially  in  adults  or  elderly 
reporting  less  than  one  bowel  movement 
per day, and evacuation disorders.  Health claims related to non-characterised microorganisms (further assessment) 
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Conditions of use 
The target population is represented by adults, and especially the elderly with an impaired peristalsis and altered bowel habits (number of weekly bowel 
movements < 7, evacuation disorders as straining at evacuation, hard faeces or anal itching, burning, or pain during or after defecation). A relatively reduced 
peristalsis is pretty normal in adult population after 50 years of age, and especially in the elderly.  
Subjects with a slightly impaired intestinal motility function and altered bowel habits (i.e. less frequent bowel movements, unsatisfactory sensation of 
complete emptying) could take advantage from the intake of Bifidobacterium adolescentis BA 02 for at least 15 days at a concentration of 10 billion viable 
cells/day.  
The microorganism Bifidobacterium adolescentis BA 02, which is the subject of the present claim, should be consumed for at least 15 days at a 
concentration of 10 billion viable cells/day in order to achieve the positive health effect. The subjects are normally directed to take the probiotic once a day, 
preferably early in the morning or late in the evening in order to be on an empty stomach. It is reasonable to assume that this quantity could be consumed as 
part of a balanced diet, especially if formulated in the form of a food supplement.  
There are no specific restrictions of use. The absence of any side effect or complication was noted throughout the course of the study in subjects taking 10 
billion viable cells/day. It is well known that probiotics, notably the strains belonging to a species with a Qualified Presumption of Safety (QPS), could be 
consumed in amounts up to 1011-1012 viable cells/day without any health risk. There are many products on the market containing up to 500 billion of 
viable cells per dose of a probiotic belonging to a QPS species. No health risk has ever been reported so far. The species Bifidobacterium adolescentis is 
included in the QPS list.  
The general recommendation is to take probiotics on an empty stomach and to rehydrate the product using about half glass of cold water or other non-
carbonated drinks at temperatures not exceeding 37°C. There are no other specific directions for preparation and/or use.  
 
 
 
 
 
 
 
 
 
 Health claims related to non-characterised microorganisms (further assessment) 
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ID  Food or Food constituent  Health Relationship  Proposed wording 
3047  A combination of the five 
probiotic strains 
Bifidobacterium lactis BS 01, 
Lactobacillus rhamnosus LR 04, 
Lactobacillus rhamnosus LR 05, 
Lactobacillus plantarum LP 01 
and Lactobacillus plantarum LP 
02.  
Such combination of strains 
should be associated with 3 or 
2.5 grams of either short-chain 
fructo-oligosaccharides (scFOS) 
or galacto-oligosaccharides 
(GOS), respectively. Both fibers 
are used for their prebiotic 
properties.  
The  intake  of  a  combination  of  Bifidobacterium  lactis  BS  01, 
Lactobacillus  rhamnosus  LR  04,  Lactobacillus  rhamnosus  LR  05, 
Lactobacillus plantarum LP 01 and Lactobacillus plantarum LP 02 is able 
to  reduce  the  incidence,  severity  and  duration  of  Acute  Respiratory 
Infections  (ARI),  especially  during  the  cold  season.  The  efficacy  was 
demonstrated  with  the  five  strains  in  association  with  3  grams  of  a 
prebiotic  fibre,  either  short-chain  fructo-oligosaccharides  (scFOS)  or 
galacto-oligosaccharides  (GOS),  specifically  selected  to  enhance  the 
colonization of the gut by the probiotic component.  
Contributes  to  reduce  the  incidence, 
duration  and  severity  of  symptoms  of 
Acute Respiratory Infections, including flu 
and  influenza-like  illnesses,  especially 
during the cold season.  Health claims related to non-characterised microorganisms (further assessment) 
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Conditions of use 
The target population is represented by normal adults. As a matter of fact, subjects enrolled in the placebo group are fully representative of the general 
population and the overall incidence of ARI in such group reflected the incidence of ARI in the general population. Subjects were completely healthy at 
enrolment without any symptom.  
Adult subjects could take advantage from the intake of B. lactis BS 01, L. rhamnosus LR 04, L. rhamnosus LR 05, L. plantarum LP 01 and L. plantarum LP 
02 for at least 90 days (or, in any case, till the end of the cold season) at a concentration of 15 total billion viable cells/day.  
The combination of B. lactis BS 01, L. rhamnosus LR 04, L. rhamnosus LR 05, L. plantarum LP 01 and L. plantarum LP 02, which is the subject of the 
present claim, should be consumed for at least 90 days (or, in any case, till the end of the cold season) at a concentration of 15 total billion viable cells/day 
in order to achieve the positive health effect. In detail, the daily effective dose is 5 billion viable cells of B. lactis BS 01, 2.5 billion viable cells of L. 
rhamnosus LR 04, 2.5 billion viable cells of L. rhamnosus LR 05, 2.5 billion viable cells of L. plantarum LP 01 and 2.5 billion viable cells of L. plantarum 
LP 02. The subjects are directed to take the probiotics once a day, preferably early in the morning or late in the evening in order to be on an empty stomach. 
It is reasonable to assume that this quantity could be consumed as part of a balanced diet, especially if formulated in the form of a food supplement.  
There are no specific restrictions of use. The absence of any side effect or complication was noted throughout the course of the study in subjects taking 15 
total billion viable cells/day for 90 consecutive days. It is well known that probiotics, notably the strains belonging to a species with a Qualified Presumption 
of Safety (QPS), could be consumed in amounts up to 1011-1012 viable cells/day without any health risk. There are many products on the market containing 
up to 500 billion of viable cells per dose of a probiotic belonging to a QPS species. No health risk has ever been reported so far. The species 
Bifidobacterium lactis, Lactobacillus rhamnosus and Lactobacillus plantarum are included in the QPS list.  
The general recommendation is to take probiotics on an empty stomach and to rehydrate the product using about half glass of cold water or other non-
carbonated drinks at temperatures not exceeding 37°C. There are no other specific directions for preparation and/or use.  
ID  Food or Food constituent  Health Relationship  Proposed wording 
3056  Bifidobacterium longum W11  The intake of Bifidobacterium longum W11 is able to relieve symptoms 
typically  associated  with  Irritable  Bowel  Syndrome  (IBS),  especially 
abdominal  discomfort  and  bloating,  and  to  restore  a  physiological 
intestinal motility in IBS subjects with a slightly to moderately decreased 
peristalsis  (number  of  weekly  evacuations  less  than  7).  This  beneficial 
effect  was  particularly  evident  in  adults  suffering  from  constipation-
predominant IBS enrolled in the first efficacy study (Colecchia A. et al. 
Minerva Gastroenterol Dietol, 2006) and in the second study (Dughera L. 
et al. Acta Biomed, 2007). The two studies had therefore the same target 
population.  
Contributes  to  reducing  intestinal 
discomfort  and  abdominal  bloating  in 
Irritable  Bowel  Syndrome,  especially  if 
constipation-predominant, and to restoring 
a physiological intestinal transit. Health claims related to non-characterised microorganisms (further assessment) 
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Conditions of use 
The target population is represented by adults suffering from Irritable Bowel Syndrome, especially constipation-predominant IBS, or from a moderately 
reduced intestinal motility and number of weekly evacuations. 
Subjects reporting IBS symptoms, especially abdominal pain and bloating in constipation-predominant IBS, or a moderately decreased intestinal motility 
function could take advantage from the intake of Bifidobacterium longum W11 for at least 36 days at a concentration of 5 billion viable cells/day. 
The strain Bifidobacterium longum W11, which is the subject of the present claim, should be consumed for at least 36 days at a concentration of at least 5 
billion viable cells/day in order to achieve the positive claimed effect on constipationpredominant IBS. The second study, dealing with constipation-type 
IBS subjects as well, demonstrated the efficacy of 5 billion viable cells/day when consumed for 3 months. In any case, the first study enrolled the higher 
number of subjects and demonstrated the efficacy as well, therefore it is possible to assume that 36 days are sufficient to mediate the claimed effect. A 
prolonged intake of the same symbiotic formulation beyond 36 days is able to maintain the beneficial effect over time. It is interesting to note that in both 
studies each active dose included also short chain fructo-oligosaccharides (2,500 mg). The daily intake of this prebiotic fiber, specifically used to enhance 
gut colonization by the probiotic, is 2,500 mg. The subjects are normally directed to take the probiotic once a day, preferably early in the morning (before 
breakfast) or in the evening (before dinner or just before going to bed) in order to be on an empty stomach. It is reasonable to assume that this quantity could 
be consumed as part of a balanced diet, especially if formulated in the form of a food supplement. 
There are no specific restrictions of use. The absence of any side effect or complication was noted throughout the course of the two studies in subjects 
taking 5 billion viable cells/day. It is well known that probiotics, notably the strains belonging to a species with a Qualified Presumption of Safety (QPS), 
could be consumed in amounts up to 1011-1012 viable cells/day without any health risk. There are many products on the market containing up to 500 billion 
of viable cells per dose of a probiotic belonging to a QPS species. No health risk has ever been reported so far. The species Bifidobacterium longum is 
included in the QPS list. 
The general recommendation is to take probiotics on an empty stomach and to rehydrate the product using about half glass of cold water or other non-
carbonated drinks at temperatures not exceeding 37°C. There are no other specific directions for preparation and/or use. 
 
 
 
 
 
 
 
 Health claims related to non-characterised microorganisms (further assessment) 
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ID  Food or Food constituent  Health Relationship  Proposed wording 
3059  The food constituent is a 
combination of the three 
probiotic strains 
Bifidobacterium lactis BS 01, 
Lactobacillus rhamnosus LR 04 
and Lactobacillus plantarum LP 
02 with lactoferrin. Such 
combination of strains should be 
associated with 3 grams of 
short-chain fructo-
oligosaccharides (scFOS), used 
for their prebiotic properties.  
The  intake  of  a  combination  of  Bifidobacterium  lactis  BS  01, 
Lactobacillus rhamnosus LR 04 and Lactobacillus plantarum LP 02 with 
lactoferrin  is  able  to  reduce  the  incidence,  severity  of  symptoms  and 
duration of Acute Respiratory Infections (ARI), especially during the cold 
season.  The  efficacy  was  demonstrated  with  the  three  strains  and 
lactoferrin in association with 3 grams of the prebiotic fibre short-chain 
fructo-oligosaccharides  (scFOS),  specifically  selected  to  enhance  the 
colonization of the gut by the probiotic component.  
Contributes  to  reduce  the  incidence, 
duration  and  severity  of  symptoms  of 
Acute Respiratory Infections, including flu 
and  influenza-like  illnesses,  especially 
during the cold season.  Health claims related to non-characterised microorganisms (further assessment) 
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Conditions of use 
The target population is represented by normal adults. As a matter of fact, subjects enrolled in the placebo group are fully representative of the general 
population and the overall incidence of ARI in such group reflected the incidence of ARI in the general population. Subjects were completely healthy at 
enrolment without any symptom.  
Adult subjects could take advantage from the intake of B. lactis BS 01, L. rhamnosus LR 04 and L. plantarum LP 02 with lactoferrin for at least 90 days (or, 
in any case, till the end of the cold season) at a concentration of 10 billion viable cells of each strain/day.  
The combination of B. lactis BS 01, L. rhamnosus LR 04 and L. plantarum LP 02 with lactoferrin, which is the subject of the present claim, should be 
consumed for at least 90 days (or, in any case, till the end of the cold season) at a concentration of 10 billion viable cells of each strain/day in order to 
achieve the positive health effect. Lactoferrin should be consumed at a rate of 0.3 grams per day.  
The subjects are directed to take the probiotic with lactoferrin once a day, preferably early in the morning or late in the evening in order to be on an empty 
stomach. It is reasonable to assume that this quantity could be consumed as part of a balanced diet, especially if formulated in the form of a food 
supplement. 
There are no specific restrictions of use. The absence of any side effect or complication was noted throughout the course of the study in subjects taking 10 
billion viable cells of each strain/day for 90 consecutive days. It is well known that probiotics, notably the strains belonging to a species with a Qualified 
Presumption of Safety (QPS), could be consumed in amounts up to 1011-1012 viable cells/day without any health risk. There are many products on the 
market containing up to 500 billion of viable cells per dose of a probiotic belonging to a QPS species. No health risk has ever been reported so far. The 
species Bifidobacterium lactis, Lactobacillus rhamnosus and Lactobacillus plantarum are included in the QPS list.  
The general recommendation is to take probiotics on an empty stomach and to rehydrate the product using about half glass of cold water or other non-
carbonated drinks at temperatures not exceeding 37°C. There are no other specific directions for preparation and/or use.  Health claims related to non-characterised microorganisms (further assessment) 
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GLOSSARY AND ABBREVIATIONS 
BCCM/LMG  Belgian  Co-ordinated  Collections  of  Microorganisms/Laboratorium  voor 
Microbiologie, Universiteit Gent 
DNA    Deoxyribonucleic acid  
DP    Degree of polymerisation 
DSMZ    Deutsche Sammlung von Mikroorganismen und Zellkulturen, Germany 
ERIC-PCR  Enterobacterial repetitive intergenic consensus PCR 
FOS    Fructo-oligosaccharides  
GOS    Galacto-oligosaccharides 
MLST    Multi-locus sequence typing 
PAGE    Polyacrylamide gel electrophoresis 
PCR    Polymerase chain reaction 
PFGE    Pulsed field gel electrophoresis 
RAPD    Randomly amplified polymorphic DNA 
Rep-PCR  Repetitive extragenomic palindromic – PCR 
RNA    Ribonucleic acid  